MARIA M4:clinical evaluation of a prototype ultrawideband radar scanner for breast cancer detection by Preece, Alan W et al.
                          Preece, A. W., Craddock, I. J., Shere, M. H., Jones, L. I. L., & Winton, H. L.
(2016). MARIA M4: clinical evaluation of a prototype ultrawideband radar
scanner for breast cancer detection. Journal of Medical Imaging, 3(3),
[033502]. DOI: 10.1117/1.JMI.3.3.033502
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1117/1.JMI.3.3.033502
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via SPIE at
http://medicalimaging.spiedigitallibrary.org/article.aspx?articleid=2537102. Please refer to any applicable terms
of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
MARIA M4: clinical evaluation of a
prototype ultrawideband radar
scanner for breast cancer detection
Alan W. Preece
Ian Craddock
Mike Shere
Lyn Jones
Helen L. Winton
Alan W. Preece, Ian Craddock, Mike Shere, Lyn Jones, Helen L. Winton, “MARIA M4: clinical evaluation
of a prototype ultrawideband radar scanner for breast cancer detection,” J. Med. Imag. 3(3),
033502 (2016), doi: 10.1117/1.JMI.3.3.033502.
MARIA M4: clinical evaluation of a prototype
ultrawideband radar scanner for breast
cancer detection
Alan W. Preece,a,* Ian Craddock,b Mike Shere,c Lyn Jones,c and Helen L. Wintond
aBristol University, School of Clinical Sciences, Southwell Street, Bristol BS2 8EJ, United Kingdom
bBristol University, School of Electrical and Electronic Engineering, Merchant Venturers Building, Woodland Road, Bristol BS8 1UB,
United Kingdom
cNorth Bristol NHS Trust, Bristol Breast Care Centre, Southmead Hospital, Bristol BS10 5NB, United Kingdom
dMicrima Limited, The Engine Shed, Station Approach, Bristol BS1 6QH, United Kingdom
Abstract. A microwave imaging system has been developed as a clinical diagnostic tool operating in the 3- to
8-GHz region using multistatic data collection. A total of 86 patients recruited from a symptomatic breast care
clinic were scanned with a prototype design. The resultant three-dimensional images have been compared
“blind” with available ultrasound and mammogram images to determine the detection rate. Images show the
location of the strongest signal, and this corresponded in both older and younger women, with sensitivity of
>74%, which was found to be maintained in dense breasts. The pathway from clinical prototype to clinical evalu-
ation is outlined. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of
this work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.JMI.3.3.033502]
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1 Introduction
Breast cancer (BC) is the most frequently diagnosed cancer in
women worldwide, with nearly 1.7 million new cases diagnosed
in 2012, and more than half of BC cases and deaths occurring in
economically developing countries.1–3 Asian countries, which
represent 59% of the global population, have the largest burden
of BC, with 39% of new cases, followed by Europe at 28%.3,4
In 2012, deaths from BC in the USA accounted for 783,000
years of potential life lost and an average of 19 years of life
lost per death.5 Early detection has been shown to be associated
with reduced BC morbidity and mortality6,7 and the goal of BC
screening programs is to reduce both. Most BCs are detected
due to clinical symptoms or by screening mammography
(MMG). The standard way to assess suspicious lesions is
with the so-called triple assessment: clinical examination, imag-
ing by MMG and ultrasound (US), and image-guided needle
biopsy. Magnetic resonance imaging is currently used for initial
cancer detection in women at high risk of developing BC but is a
complex investigation with high direct and indirect costs.8–11
MMG is one of the most effective detection techniques, but suf-
fers from relatively low sensitivity, entails exposure to ionizing
radiation and also involves uncomfortable compression of the
breast. MMG also performs less well in younger, more dense
breasts, which is pertinent as breast density is now established
as an independent risk factor for developing BC irrespective of
other known risk factors.12–16 This coupled with the increased
risk from ionizing radiation in younger women, restricts the
lower age for use based on risk/benefit ratio. Limitations of
MMG have resulted in research into alternative methods for
imaging of breasts with microwave detection of breast tumors
being a potential nonionizing alternative.17 Initial results of
microwave radar-based imaging have been presented17–23 and
approaches rely on a difference in the dielectric properties
(Dk) of normal and malignant breast tissues.24–31 The breast
as an organ is unique in the human body in that basic structure
consists of glandular tissue (high dielectric constant, high
conductivity, and radioopaque) in a fat (low dielectric constant,
low conductivity, and relatively radiolucent)-based matrix.
Inclusions, such as a tumor, are also of high permittivity,
enhanced by the angiogenic increase in vascularity, and cysts
contain fluid, which also have very high permittivity.
Some early measurements at 3.2 GHz26 indicate that the most
common relative permittivity values for breast fat were 4 to 4.5,
for normal glandular tissue 10 to 25 and for malignant tissues 45
to 60, but overlaps occurred so that values up to 55 and down to
10 for normal and malignant tissues, respectively, occurred.
Glandular tissue is distributed whereas malignant and cystic tis-
sue tends at diagnosis to be discrete and, therefore, much easier
to image. Similar results were obtained using completely differ-
ent measurement techniques by Sugitani et al.32 showing overlap
of tissue values.
Such inclusions alter the speed of propagation of radio waves
passing through the tissue and the higher conductivity results in
radio wave absorption. These changes mean that the phase and
amplitude of a signal is affected by inclusions. In order to image
inclusions, an array of antennas transmit signals in turn to be
detected by all the other nontransmitting antennas—a so-called
multistatic array. The choice of frequency for such a radar sys-
tem is a compromise between absorption of radio waves (which
increases with frequency) and resolution (which increases with
decreasing wavelength). Availability of a suitable radio wave
transmitter and receiver [in this case, a vector network analyzer
(VNA)] is also a factor. An ultrawideband (UWB) signal from 3
to 8 GHz is used in this development.
*Address all correspondence to: Alan W. Preece, E-mail: A.W.Preece@bristol.
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2 Methods and Materials
A series of prototype MARIA radar scanners were constructed
within the Electrical and Electronic Engineering Department of
the University of Bristol with funding from Micrima Ltd. All
systems were based on multistatic radar operation, originally
proposed for land mine detection by Benjamin.33 Prototypes
have evolved from an initial 16-antenna array34 through to a
31-element UWB slot antenna system (MARIA M3).35 To
increase the number of antennas, arrays have been redesigned
with new smaller UWB antennas. For improved imaging
performance and reduced scanning times, a new 60-element
antenna array system has been designed (MARIA M4).36
This system consists of 60 wide-slot antenna elements posi-
tioned in a hemispherical arrangement.36,37 The antennas operate
over a frequency range of 3 to 8 GHz in a cavity loaded
slot arrangement.38 Each antenna is designed to couple into a
dielectric constant environment of Dk ¼ 10.
To interface the antenna into tissue and to provide a fixed
spacer to place the imaged tissue volume in the antenna far
field, a separate fixed coupling shell with a uniform Dk ¼ 10 is
employed between the antennas and the breast tissue. This shell
leaves a space between the antenna face and the shell is filled
with a water-/oil-based coupling fluid also with a Dk ¼ 10.
The coupling shell and coupling fluid allows the antenna
array not only to match the antenna into its surrounding
environment and provide maximum radiated power, but as
importantly, provides a method to allow the antenna array to
rotate underneath the fixed shell. The system signal source is
a VNA operating in the range of 3 to 8 GHz employing standard
stepped continuous wave mode. To couple the antennas to the
VNA source/receiver, a low-loss high-isolation switch matrix
allows a single signal to be connected to any one of the 60
antennas and groups of receiving antenna signals to be, simul-
taneously, received at the VNA
The system collects signal data from the finished array by
serially energizing each antenna and collecting the scattering
parameter values at each incident frequency from the receive
signals collected at all remaining antennas. This method results
in a set of signal data for each of the bistatic ray paths. Due to
antenna reciprocity, we can reduce the number of bistatic signals
collected to half of the 3540/2 or 1770. This reduces the overall
scan time.
As signals are transmitted from each antenna, every signal
passes through the external coupling shell and into the tissue
volume. Multiple reflections occur within the antenna array
and its associated coupling shell and coupling fluid and at the
interface between the coupling shell and the breast skin surface.
The breast skin surface has an estimated Dk of 25, so a signifi-
cant portion of the incident signal is reflected (depending on its
incident angle at this interface). Signals that penetrate into tissue
are then reflected at random angles from the surfaces of tissue
dielectric discontinuities within the tissue volume.
The various tissue types found in the breast have clearly
identifiable dielectric constants in the microwave frequency
range,27,32 which result in incident signals being reflected and
attenuated differently at each interface between the tissue types.
It is these signals the system collects and accumulates at each
point in the estimated tissue space. These intratissue response
signals are very small in comparison to the signals from the
hardware/skin reflection signals that also appear in the final sig-
nal set; thus, a method to remove the nontissue generated signals
from the final set is necessary before image generation.
Each complete image scan of the breast is a result of two
separate scans offset from one another by a fixed angle.
Unwanted signals produced by hardware and skin reflections
are almost identical and appear at the same time position in
each scan; therefore, they can be eliminated. In contrast, a
tumor response will appear at different time positions in these
two measured sets (except on the axis of rotation).
During image generation the single scans are subtracted from
one another. This leaves the “nonstationary” signals intact and
significantly reduces the “stationary” signals so that the signals
generated by the tissue volume reflections predominate.
Image generation from the resulting RF signal data makes a
number of assumptions. We assume that within the angle of
array rotation (a) distance between antennas and skin remains
unchanged, (b) skin properties and thickness are the same,
(c) normal breast tissue properties do not change, and (d) a uni-
form dielectric constant of Dk ¼ 10 exists with the hardware
and breast tissue across all frequencies of interest. These
assumptions allow an estimate to be made of the location of
a received signal based on the time-of-flight to and from the
target location and based on the transition time of signals at
each frequency in a medium whose Dk ¼ 10.
To generate the image, the system uses a modified version of
the classical delay-and-sum (DAS) beamforming algorithm.23,39,40
First, we perform the preprocessing steps, consisting of extrac-
tion of the tumor response from measured data,23 equalization of
tissue losses, and then equalization of radial spread of the spheri-
cal wavefront. Next, appropriate time delays for all received
signals are computed. The time delay for a given transmitting
and receiving antenna is calculated based on the antenna’s
position, position of the focal point r ¼ ðx; y; zÞ, as well as
an estimate of average wave propagation speed, which in our
case is assumed to be constant across the band. During the
focusing, the focal point moves from one position to another
within the breast; at each location, all time-shifted responses
are coherently summed and integrated. Integration is performed
on the windowed signal, and the length of the integration win-
dow is chosen according to the system bandwidth, which is
50% longer than the synthetic pulse duration and was set to
0.55 ns,23 to form a three-dimensional (3-D) map of scattered
energy. The main advantage of the DAS algorithm is its simplic-
ity, robustness, and short computation time.
The 3-D map of spatial energy is presented to the user as a
colored image comprising slices along three axes: craniocaudal
(CC), mediolateral, and physician point-of-view. The energy
image is normalized to the maximum energy value within
the image. The image presented to the reader is thresholded
(calibrated) at 70% of the maximum, which corresponds to
the significant scatters within the breast as determined through
extensive phantom experimental work.35 Typically energy
values less than 70% of the maximum correspond to clutter.
An isometric 3-D rotatable image is provided showing an
iso-surface representation of the energy values whose relative
contrast is adjustable by the image reader.
2.1 Clinical Equipment
The microwave components and supporting mechanical parts
are incorporated into a fully integrated bed/system cabinet
design (Fig. 1).The antenna array position is adjustable with
the patient in position on the bed. It can be raised and lowered
and is provided with lateral and cranial/caudal adjustment to
allow the operator to optimally position the breast within the
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scanning cup in terms of fit without the patient having to move
during normal clinical application. The system cabinet can also
be rotated out from under the bed to allow introduction of addi-
tional inserts designed to accommodate smaller breast cup sizes
into the basic breast cup [Fig. 1(c)].
2.2 Patient Population
The MARIA M4 prototype system was initially tested for
efficacy in women attending symptomatic breast care clinics.
Eighty-six patients were identified by clinicians as meeting
study inclusion criteria [symptomatic clinic, to be examined
by US and MMG, able to lie prone and having breast size within
the range of available cups (310 to 850 ml)] and after giving
informed consent were recruited at either Frenchay or
Southmead Hospital, Bristol, U.K., and included in the
observational, prospective MARIA M4 clinical evaluation
study [approved by Central and South Bristol Research
Ethics Committee (REC) 06/Q2006/30]. The type of lesions
included were mainly cysts and cancers but a small number
of “other” conditions that had mammogram and US were
included. These conditions were a mix of hematoma, lipoma,
or fibroadenoma.
2.3 Procedure in Clinic
Patients had an US examination and MMG, and where possible
a cytology or histology examination (if appropriate and for
patient benefit) as part of normal clinical procedure. Patients
were scanned using MARIA M4 prior to any surgical or biopsy
intervention. Patients were required to lie prone with the breast
inserted into a ceramic cup lined with a small amount of
“coupling fluid” of dielectric constant 10 and attenuation of
0.8 dB∕cm at 3 GHz.41 The scan consisted of checks for good-
ness of fit of the breast inside the cup (lack of air gap), followed
by at least two further scans of about 30 s each. Data was proc-
essed offline.
2.4 Data Collection
Data collected were Breast Imaging Reporting and Data System
(BI-RADS) score,42 age, menopausal status, and breast size.
Evaluation of MARIA M4 scans consisted of two stages: a
judgment of lesion(s) type, size, and location using all available
clinical data by a researcher who had no knowledge of the
MARIA image, and an assessment of the MARIA image by
an engineer who had no access to the clinical data or image.
The two observations were then compared jointly by the two
observers to decide on the available data of a good correspon-
dence, failure to correspond, or a need to exclude. In this, the
results from US with or without MMGwere the “gold standard.”
Additionally, a nested evaluation was undertaken in which a
blind read of all available MMGs was completed for MARIA
M4 study patients (n ¼ 66). All patients’ identifiable informa-
tion was removed from MMGs by a patient archiving commu-
nication system (PACS) administrator and a blind read of the
MMG was conducted by an experienced radiologist. Blind
read results were compared to the original clinical result using
all available clinical information and to MARIA M4 detection
(versus “gold standard” results).
3 Results
Of 86 MARIA M4 patients included in the study, a sensitivity
score of 74% (64/86) correspondence with the “gold standard”
(mean age 51.4 years, age range 24 to 87, diagnoses: cysts
n ¼ 36 (57%), cancer n ¼ 20 (31%), others n ¼ 8 (12%) was
obtained (Table 1). Before reviewing a MARIA image, the
location of the lesion within the breast was recorded on the
basis of octant of breast, depth on US (allowing for degree of
compression by the probe), and distance from the nipple as
noted in clinical and imaging examinations. The sensitivity
was judged by whether MARIA located an apparent lesion in
the corresponding position, making subjective allowance for
US probe compression and MMG breast compression. The
MARIA image was produced by an engineer “blind” to the clini-
cal status. On this basis there was 75% (45/60) sensitivity in pre/
peri-menopausal women and 73% (19/26) in postmenopausal
women. An example of a MARIA M4 scan is given at 70%
threshold within the image [Fig. 2(a)].
Of the initial 86 studies reviewed, 66 had a MMG available
for comparison. Of these cases there was 74% (49/66) sensitivity
for MARIA M4 compared to MMG (Table 2). Sensitivity was
Fig. 1 MARIA M4/M5 array and bed system. (a) Latest design rotat-
able 60 antenna array and switch assembly which moves as a unit
around the breast cup. (b) MARIA M4 in position in the clinic.
(c) MARIA M5 operationally identical to M5 design but in a clinically
more acceptable and integrated package as currently in use.
Table 1 Patient demographics, sensitivity scores and diagnoses for MARIA M4 detection (versus gold standard).
Cases n ¼ 86 Sensitivity score Mean age (years) Age range (years) Cysts Cancer Others
All 86 64 (74%) 51.4 24 to 87 36 (57%) 20 (31%) 8 (12%)
Pre/peri-menopausal 60 45 (75%) 45.5 24 to 57 28 (62%) 10 (22%) 7 (16%)
Postmenopausal 26 19 (73%) 67 46 to 87 8 (42%) 10 (53%) 1 (5%)
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86% (36/42) in MMG dense breasts (BI-RADS c or d), which
was a 17% increase compared to the original clinical review
(69%) and a 7% increase compared to the blind review (79%).
Examples of MARIA images are given for a grade 3 invasive
ductal carcinoma (B5b), where there was good correspondence
with the US (U5) and where the MMG was marked as normal
(M1) by the original radiologist and an experienced radiologist
(Fig. 3). For comparison, a negative example of MARIA is
shown in which conventional methods (US and MMG) were
successful (Fig. 4).
4 Discussion
Although the number of subjects analyzed here is too small to
permit extensive statistical comparisons, nevertheless, some
trends can be demonstrated. A detection rate of 74% in all 86
breasts scanned compares very well to the 78% score in digital
MMG reported in the digital mammographic imaging screening
trial (DMIST) study.43 Further improved results in dense breasts
at 86% compares even more favorably to the DMIST dense breast
group at 78% and these MARIA results in dense breasts is impor-
tant as women with dense tissue in 75% or more of the breast
have a risk of BC four to six times as great as the risk among
women with little or no dense tissue.13–15,44,45 Patients undergoing
a MARIA scan reported that the procedure was acceptable and
easily managed by those able to lie prone, and still, for about
2 min and particularly appreciated the lack of breast compression.
As the incidence of BC has increased and ∼25% of all deaths due
to BC occur in the 40- to 49-year-old age group,46,47 the MARIA
system has potential to provide a major impact in improving BC
screening. The MARIA system produces a high-contrast 3-D
image of the breast and offers the provision of a safer, more com-
fortable, and inexpensive breast screening alternative compared to
other modalities, which has been shown to be particularly effec-
tive at detecting cancer in younger, premenopausal women with
dense breasts. MARIA may also overcome some of the chal-
lenges posed by trying to optimize the balance between benefit
and harm of MMG screening in women of younger age. An
improved MARIA M5 system with full CE marking is currently
undergoing additional clinical evaluation (approved by Yorkshire
& The Humber and South Yorkshire REC 15/YH/0084,
ClinicalTrials.gov NCT02493595).
Fig. 2 An example of a MARIA scan compared with a mammogram (MMG) and US. (a) MARIA M4 scan
[max focused strength at (X ¼ 3, Y ¼ 21, Z ¼ −42 mm)], (b) US scan, and (c) MMG. Clinical diagnoses:
carcinoma 17 mm and liquid-filled milk duct. Only tumor is visible on mammogram. Both carcinoma and
liquid-filled milk duct are visible on MARIA M4 and US scans.
Table 2 Comparison of MARIA M4 detection compared to original
radiologist report and a “Blind” review.
Characteristic
MARIA M4
(n ¼ 66)
Original
radiologist
report
Single
radiologist
blind review
Correct detection 49/66 (74%) 51/66 (77%) 55/66 (83%)
Lucent (BI-RADS a+b) 13/24 (54%) 22/24 (92%) 22/24 (92%)
Dense (BI-RADS c+d) 36/42 (86%) 29/42 (69%) 33/42 (79%)
Note: Comparison between MARIA M4 correct detection rate and the
original radiographic diagnosis using all available clinical data, both
compared with a new review of radiographs alone used by a single
radiologist, using the same mix of 66 cases. We note the improved
results in dense breasts by the experienced radiologist compared
with the original results from a mix of duty radiologists notwithstanding
the additional clinical information those radiologists were using. BI-
RADS score is based on the American College of Radiologists
(fifth edition): (a) the breasts are almost entirely fatty; (b) there are
scattered areas of fibroglandular density; (c) the breasts are hetero-
geneously dense, which may obscure small masses; (d) the breasts
are extremely dense, which lowers the sensitivity of MMG.
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5 Conclusion
Microwave imaging is a rapid, potentially diagnostic technology
that is nonionizing, does not involve breast compression, and
that has been found to be able to identify regions of significant
dielectric contrast, even in dense breasts. This suggests it has
value in a routine diagnostic breast care clinic, where x-ray
MMG is known to perform suboptimally in dense tissue.13 Due
to MARIA’s completely benign radiation characteristic, the
Fig. 3 Comparison of MARIA M4 detection of B5b with US and MMG, BI-RADS c. (a) US scan (U5),
(b) MMG marked as normal (M1) by the original and experienced radiologist, (c) lateral view of right
breast using MARIA showing area of high dielectric contrast [lateral view of right breast focusing at
X ¼ 21 mm, max at (Y ¼ 3, Z ¼ −42 mm)], and (d) 3-D image of lesion using MARIA [level ¼
0.8 max at (X ¼ 21, Y ¼ 3, Z ¼ −42 mm) value = 1.413e–002].
Fig. 4 Comparison of MARIA M4 images where there was a false correspondence with conventional
methods (i.e., US and MMG) in detection of a carcinoma. (a) CC view of left breast with MARIA M4
[CC view of right breast focusing at Y ¼ 0.15 mm, max at (X ¼ 15, Z ¼ −42 mm)], (b) lateral view
of left breast with MARIA M4 [lateral view of left breast focusing at X ¼ 15 mm, max at (Y ¼ 0.15,
Z ¼ −42 mm)], (c) CC view of left breast with MMG, marked as (M5) in original trial assessment and
(M4) by experienced radiologist (LCC), and (d) left medial lateral oblique view by MMG (LMLO).
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technique lends itself to future applications within a younger
screening demographic, including women who are deemed to
be at a high risk of developing BC.
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